Methamphetamine detection in urine is extended by its metabolism into amphetamine — an active metabolite that itself has a long half-life. For occasional users, meth is detectable for 3–6 days. Chronic users can test positive for 7–14 days. Standard drug panels test for both methamphetamine and amphetamine, meaning both the parent drug and metabolite contribute to positive results.
Methamphetamine is metabolized by CYP2D6 into amphetamine (10–20% conversion) and para-hydroxymethamphetamine. The dual presence of parent drug and active metabolite creates an extended detection window compared to amphetamine alone. Approximately 40–50% of methamphetamine is excreted unchanged in urine — one of the highest unchanged excretion rates of any stimulant.
Like amphetamine, meth excretion is pH-dependent. Acidic urine dramatically increases renal clearance of both methamphetamine and amphetamine. In clinical studies, acidifying the urine reduced meth half-life from ~20 hours (alkaline pH) to ~7 hours (acidic pH). While this pharmacological principle is well-established, it does not reliably shorten detection enough to 'pass' a test with insufficient clearance time.
Confirmation testing is critical for methamphetamine cases. Immunoassay screens cannot distinguish between amphetamine and methamphetamine — both trigger positive results on the amphetamine assay. LC-MS/MS confirmation identifies the specific compound and ratio. Methamphetamine confirmation requires that the meth metabolite exceeds a minimum concentration (typically 200 ng/mL with amphetamine also present at ≥100 ng/mL).
Occasional use: 3–6 days. Chronic heavy use: 7–14 days. The active amphetamine metabolite extends detection beyond what the methamphetamine half-life alone would suggest.
No. Vyvanse (lisdexamfetamine) is metabolized to d-amphetamine only, not methamphetamine. Confirmation testing will show amphetamine without methamphetamine, clearly distinguishing prescribed use.